// App-Quantinova.ai

S185 : CIRCULATING TUMOR CELLS (CTC) ARE THE MOST RELEVANT DIAGNOSTIC BIOMARKER IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (MM)

Researchers

Presenter

  • Juan-Jos Garcs

Principal Investigators

  • Noemi Puig

  • Leire Burgos

  • Jose J Perez

  • Lourdes Cordon

  • Juan Flores-Montero

  • Luzalba Sanoja-Flores

  • Albert Oriol

  • Mara-Jess Blanchard

  • Rafael Rios

  • Jesus Martin

  • Rafael Martinez-Martinez

  • Joan Bargay

  • Anna Sureda

  • Javier De La Rubia

  • Miguel-Teodoro Hernandez

  • Paula Rodriguez-Otero

  • Alberto Orfao

  • Maria-Victoria Mateos

  • Joaquin Martinez-Lopez

  • Laura Rosiol

  • Joan Blade

  • Jesus F. San-Miguel

  • Bruno Paiva

Medical Centers

  • Cancer Research Center (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine,University of Salamanca,Salamanca,Espagne

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Institut Català d’Oncologia i Institut Josep Carreras,Barcelona,Spain

  • Hospital Ramon y Cajal, Madrid, Spain

  • Hospital Universitario Virgen del Rocio/Instituto de Biomedicina de Sevilla, Seville, Spain

  • Hospital Son Llatzer, Palma De Mallorca, Spain

  • Hospital Universitario Virgen de las Nieves, Granada, Spain

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

  • Hospital Universitario de Canarias, Santa Cruz De Tenerife, Spain

  • Institut Català d'Oncologia L’Hospitalet,Barcelona,Spain

  • Hospital Clinic, IDIBAPS, Barcelona, Spain

  • Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA),Pamplona,Spain

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC),Salamanca,Espagne

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Ixazomib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved